[Treatment of nonalcoholic steatohepatitis]

Bürgi, Anne-Catherine; Dufour, Jean-François (2012). [Treatment of nonalcoholic steatohepatitis]. Revue du praticien, 62(10), pp. 1425-7. Neuilly-sur-Seine: Global Média Santé

Full text not available from this repository. (Request a copy)

NASH associates steatosis with parenchymal inflammation and signs of hepatocellular injuy and even apoptosis. This leads in a minority of patients to fibrosis and in the long term to cirrhosis. NASH regularly occurs in a metabolic context characterized by insulin resistance. Several drugs have been tested in randomized controlled studies. Glitazones improve insulin resistance and also NASH, but are associated with side effects particularly unwelcome in NASH patients. Ursodesoxycholic acid, an hydrophilic biliary acid with hepatoprotective properties, does not improve the histological lesions of NASH. Vitamin E is the only compound which showed so far a positive effect without relevant side effects. However, it is too early to recommend its long-term use in this indication. Finally, the best treatment is not with drugs, but relies on behavioural changes: NASH patients should regularly exercise!

Item Type:

Journal Article (Further Contribution)


04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology

UniBE Contributor:

Dufour, Jean-François




Global Média Santé




Factscience Import

Date Deposited:

04 Oct 2013 14:38

Last Modified:

06 Dec 2013 13:37

PubMed ID:



https://boris.unibe.ch/id/eprint/15198 (FactScience: 222490)

Actions (login required)

Edit item Edit item
Provide Feedback